Table 1 Correlations between different forms of soluble PD-L1 and clinicopathological features in patients with stage I-III colorectal cancer
sPD-L1 | secPD-L1 | exoPD-L1 | |||||||
|---|---|---|---|---|---|---|---|---|---|
High N (%) | Low N (%) | p-value | High N (%) | Low N (%) | p-value | High N (%) | Low N (%) | p-value | |
Gender | 0.324 | 0.324 | |||||||
Male | 20 (55.56) | 20 (55.56) | 22 (55.00) | 18 (45.00) | 22 (55.00) | 18 (45.00) | |||
Female | 9 (20.00) | 9 (20.00) | 0.427 | 12 (42.86) | 16 (57.14) | 12 (42.86) | 16 (57.14) | ||
Age | 0.089 | 0.808 | |||||||
 ≤ 60 | 12 (42.86) | 12 (42.86) | 13 (39.39) | 20 (60.61) | 16 (48.48) | 17 (51.52) | |||
 > 60 | 17 (53.13) | 17 (53.13) | 1.000 | 21 (60.00) | 14 (40.00) | 18 (51.43) | 17 (48.57) | ||
Location of primary | 0.253 | 0.253 | |||||||
Left | 24 (48.00) | 24 (48.00) | 28 (53.85) | 24 (46.15) | 28 (53.85) | 24 (46.15) | |||
Right | 5 (50.00) | 5 (50.00) | 0.073 | 6 (37.50) | 10 (62.50) | 6 (37.50) | 10 (62.50) | ||
Histology | 0.021 | 0.323 | |||||||
Adenocarcinoma | 21 (42.86) | 21 (42.86) | 25 (43.86) | 32 (56.14) | 27 (47.37) | 30 (52.63) | |||
MC or SRCC | 8 (72.73) | 8 (72.73) | 0.915 | 9 (81.82) | 2 (18.18) | 7 (63.64) | 4 (36.36) | ||
Differentiation | 0.720 | 0.162 | |||||||
Poor | 6 (46.15) | 6 (46.15) | 8 (53.33) | 7 (46.67) | 5 (33.33) | 10 (66.67) | |||
Well/Moderate | 22 (47.83) | 22 (47.83) | 0.796 | 25 (48.08) | 27 (51.92) | 28 (53.85) | 24 (46.15) | ||
Tumor size (cm) | 0.627 | 0.627 | |||||||
≧4.5 | 15 (50.00) | 15 (50.00) | 17 (51.13) | 15 (46.88) | 15 (46.88) | 17 (53.13) | |||
< 4.5 | 14 (46.67) | 14 (46.67) | 0.511 | 17 (47.22) | 19 (52.78) | 19 (52.78) | 17 (47.22) | ||
T | 0.300 | 1.000 | |||||||
T1-2 | 8 (42.11) | 8 (42.11) | 9 (40.91) | 13 (59.09) | 11 (50.00) | 11 (50.00) | |||
T3-4 | 21 (51.22) | 21 (51.22) | 0.897 | 25 (54.35) | 21 (45.65) | 23 (50.00) | 23 (50.00) | ||
Lymph node metastasis | 1.000 | 0.549 | |||||||
N0 | 23 (47.92) | 23 (47.92) | 27 (50.00) | 27 (50.00) | 28 (51.85) | 26 (48.15) | |||
N1-2 | 6 (50.00) | 6 (50.00) | 1.000 | 7 (50.00) | 7 (50.00) | 6 (42.86) | 8 (57.14) | ||
Perineural invasion | 0.692 | 0.771 | |||||||
Absent | 24 (48.98) | 24 (48.98) | 26 (47.27) | 29 (52.73) | 27 (49.09) | 28 (50.91) | |||
Present | 5 (55.56) | 5 (55.56) | 0.203 | 6 (60.00) | 4 (40.00) | 6 (60.00) | 4 (40.00) | ||
Vessel invasion | 0.200 | 0.871 | |||||||
Absent | 17 (43.59) | 17 (43.59) | 19 (43.18) | 25 (56.82) | 21 (47.73) | 23 (52.27) | |||
Present | 10 (62.50) | 10 (62.50) | 0.897 | 11 (61.11) | 7 (38.89) | 9 (50.00) | 9 (50.00) | 0.549 | |
TNM classification | 1.000 | ||||||||
Stage I/II | 23 (47.92) | 23 (47.92) | 27 (50.00) | 27 (50.00) | 28 (51.85) | 26 (48.15) | |||
Stage III | 6 (50.00) | 6 (50.00) | 0.438 | 7 (50.00) | 7 (50.00) | 6 (42.86) | 8 (57.14) | 0.056 | |
MMR status | 0.203 | ||||||||
dMMR | 7 (58.33) | 7 (58.33) | 8 (66.67) | 4 (33.33) | 9 (75.00) | 3 (25.00) | 0.324 | ||
pMMR | 22 (45.83) | 22 (45.83) | 26 (46.43) | 30 (53.57) | 0.324 | 25 (44.64) | 31 (55.36) | ||